EGFR and malignant colon neoplasm: Our findings demonstrate that overproduction of HGF can underlie primary resistance to EGFRi in colon cancer cells that harbor WT KRas and suggest that these patients may benefit from combined therapy with inhibitors of EGFR and HGF.